# A Phase 3 Study Comparing TLL-018 to Tofacitinib in RA Subjects With Inadequate Response or Intolerance to bDMARDs

> **NCT06020144** · PHASE3 · UNKNOWN · sponsor: **Hangzhou Highlightll Pharmaceutical Co., Ltd** · enrollment: 450 (estimated)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** TLL-018
- **DRUG:** Tofacitinib

## Key facts

- **NCT ID:** NCT06020144
- **Lead sponsor:** Hangzhou Highlightll Pharmaceutical Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-11-15
- **Primary completion:** 2025-02-28
- **Final completion:** 2025-09-30
- **Target enrollment:** 450 (ESTIMATED)
- **Last updated:** 2023-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06020144

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06020144, "A Phase 3 Study Comparing TLL-018 to Tofacitinib in RA Subjects With Inadequate Response or Intolerance to bDMARDs". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06020144. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*